188 related articles for article (PubMed ID: 29080447)
1. Epidemiology of malignant peritoneal mesothelioma: A population-based study.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Cancer Epidemiol; 2017 Dec; 51():81-86. PubMed ID: 29080447
[TBL] [Abstract][Full Text] [Related]
2. Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
Salo SAS; Ilonen I; Laaksonen S; Myllärniemi M; Salo JA; Rantanen T
Anticancer Res; 2019 Feb; 39(2):839-845. PubMed ID: 30711965
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal mesothelioma mortality in Italy: Spatial analysis and search for asbestos exposure sources.
Zona A; Fazzo L; Minelli G; De Santis M; Bruno C; Conti S; Comba P
Cancer Epidemiol; 2019 Jun; 60():162-167. PubMed ID: 31030080
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study.
Salo SAS; Lantto E; Robinson E; Myllärniemi M; Laaksonen S; Salo JA; Rantanen T; Ilonen I
Sci Rep; 2020 Aug; 10(1):13257. PubMed ID: 32764701
[TBL] [Abstract][Full Text] [Related]
5. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.
Soeberg MJ; Creighton N; Currow DC; Young JM; van Zandwijk N
Aust N Z J Public Health; 2016 Jun; 40(3):255-62. PubMed ID: 26713662
[TBL] [Abstract][Full Text] [Related]
6. Forecast of Malignant Peritoneal Mesothelioma Mortality in Italy up to 2040.
Oddone E; Bollon J; Nava CR; Minelli G; Imbriani M; Consonni D; Marinaccio A; Magnani C; Barone-Adesi F
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33379304
[TBL] [Abstract][Full Text] [Related]
7. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
Yin W; Zheng G; Yang K; Song H; Liang Y
World J Surg Oncol; 2018 Mar; 16(1):44. PubMed ID: 29506546
[TBL] [Abstract][Full Text] [Related]
8. Malignant pleural mesothelioma in Finland: regional and gender variation.
Laaksonen S; Ilonen I; Kuosma E; Sutinen E; Wolff H; Vehmas T; Husgafvel-Pursiainen K; Salo JA; Koli K; Räsänen J; Myllärniemi M
Acta Oncol; 2019 Jan; 58(1):38-44. PubMed ID: 30375909
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal mesothelioma in Sweden: A population-based study.
Cashin PH; Jansson Palmer G; Asplund D; Graf W; Syk I
Cancer Med; 2019 Oct; 8(14):6468-6475. PubMed ID: 31483564
[TBL] [Abstract][Full Text] [Related]
10. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
[TBL] [Abstract][Full Text] [Related]
11. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
[TBL] [Abstract][Full Text] [Related]
12. Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study.
Le Stang N; Bouvier V; Glehen O; Villeneuve L; ; ; Galateau-Sallé F; Clin B
Cancer Epidemiol; 2019 Jun; 60():106-111. PubMed ID: 30953970
[TBL] [Abstract][Full Text] [Related]
13. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study.
van Kooten JP; Belderbos RA; von der Thüsen JH; Aarts MJ; Verhoef C; Burgers JA; Baas P; Aalbers AGJ; Maat APWM; Aerts JGJV; Cornelissen R; Madsen EVE
Thorax; 2022 Dec; 77(12):1260-1267. PubMed ID: 35149582
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal mesothelioma: the site of origin matters.
Kindler HL
Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
16. Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology.
Kattan J; Eid R; Kourie HR; Farhat F; Ghosn M; Ghorra C; Tomb R
Asian Pac J Cancer Prev; 2016; 17(8):4169-73. PubMed ID: 27644679
[TBL] [Abstract][Full Text] [Related]
17. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
Yin W; Zheng G; Su S; Liang Y
Oncol Res Treat; 2019; 42(6):334-341. PubMed ID: 31063993
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
19. A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype.
Valente K; Blackham AU; Levine E; Russell G; Votanopoulos KI; Stewart JH; Shen P; Geisinger KR; Sirintrapun SJ
Am J Surg Pathol; 2016 Sep; 40(9):1243-8. PubMed ID: 27438989
[TBL] [Abstract][Full Text] [Related]
20. An Occupational Legacy: Malignant Mesothelioma Incidence and Mortality in Wisconsin.
Tomasallo CD; Christensen KY; Raymond M; Creswell PD; Anderson HA; Meiman JG
J Occup Environ Med; 2018 Dec; 60(12):1143-1149. PubMed ID: 30256306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
